Cardiovascular and
cerebrovascular diseases have been major health problems and ar also the
leading causes of death for several decades. An early diagnosis is very
important because the disease often leads to sudden death with few prognostic
symptoms. Although magnetic resonance imaging
(MRI) and MRI contrast agents are widely used
to solve these problems, an early diagnosis cannot be relied upon for
identifying small blood vessels or blood vessels that have narrowed and are blocked. Furthermore, current
clinical MRI contrast agents contain toxic gadolinium ions which pose a safety
risk to patients with kidney disease.
During Tae-Hyun’s Ph.D.
course, Tae-Hyun focused on the design and synthesis of a new type of MRI
contrast agent that can meet both high-resolution and safety. Tae-Hyun and
colleagues used biocompatible ingredients of iron oxide and
polysaccharide to develop one of the highest-resolution imaging agents (code
name INV-X), which is 10 times more precise than the images generated using
current contrast agents.
In 2018, Tae-Hyun founded
Inventera to develop and commercialize the INV-X. Two years
after, Tae-Hyun initiated the world's first human trial with its non-gadolinium
high-performance MRI contrast agents INV-X. And now, Tae-Hyun is preparing for
Phase 2 clinical trials of INV-X and developing various new contrast agents
that can solve unmet clinical needs in diagnostic imaging.